Related Experiment Videos
Plasma platelet factor 4: a potentially useful predictor of ischaemic heart disease?
Insights
Plasma platelet factor 4 (PF-4) may predict future cardiac death risk in patients with suspected acute myocardial infarction (AMI). Higher PF-4 levels were linked to increased mortality from ischaemic heart disease (IHD).
Area of Science:
- Cardiology
- Biomarkers
- Clinical Research
Background:
- Acute myocardial infarction (AMI) and ischaemic heart disease (IHD) are leading causes of mortality.
- Prognostic tools are crucial for identifying high-risk patients.
- Platelet activation markers, like PF-4, may indicate cardiac events.
Purpose of the Study:
- To evaluate plasma platelet factor 4 (PF-4) as a prognostic marker in patients with suspected AMI.
- To determine if PF-4 levels can identify patients at risk for future death from AMI or IHD.
Main Methods:
- Plasma PF-4 levels were measured upon admission in 109 consecutive patients in a coronary care unit.
- Patients were categorized into AMI, IHD (no AMI), or no IHD groups.
- Mortality (in-hospital and follow-up) was assessed over an average of 16.7 months.
Main Results:
- A trend towards higher PF-4 levels was observed in patients who died of AMI compared to survivors.
- Significantly higher PF-4 levels (p < 0.05) were found in patients who died from IHD during follow-up compared to survivors.
- No deaths from non-cardiac causes were recorded.
Conclusions:
- Plasma PF-4 may serve as a useful prognostic biomarker in patients with suspected AMI.
- Elevated PF-4 levels are associated with an increased risk of mortality from IHD.
- Further research could explore PF-4's role in risk stratification for cardiac events.
Abstract:
The aim was to investigate whether plasma platelet factor 4 (PF-4) in suspected acute myocardial infarction (AMI) patients could serve as a prognostic tool and identify patients at risk for future death from AMI or ischaemic heart disease (IHD). Therefore, upon admission to our coronary care unit plasma PF-4 was measured on 109 consecutive patients. 53 of them proved to have AMI, and 50 IHD but no AMI; the remaining 6 had no evidence of IHD. 24 patients died in hospital or during the follow-up period which was an average of 16.7 +/- 2.4 months. The decreased were subgrouped into those dying of AMI (n = 16), and those dying of IHD but with no AMI (n = 8). No deaths from other causes were recorded. As compared with survivors there was a tendency towards higher PF-4 values among those who died of AMI. However, patients who during follow-up suffered death from IHD proved to have significantly (p less than 0.05) higher PF-4 levels than survivors.